<?xml version="1.0" encoding="UTF-8"?>
<p id="p0075">Inhibitors of SARS-CoV M
 <sup>pro</sup> have been reviewed comprehensively by Pillaiyar et al. in 2016.
 <xref rid="b0360" ref-type="bibr">
  <sup>72</sup>
 </xref> MERS-CoV inhibitors have been reviewed by Liang et al. in 2018.
 <xref rid="b0450" ref-type="bibr">
  <sup>90</sup>
 </xref> Peptidomimetics and small molecules have been reported with affinities in the micro- to nanomolar range. They often depend on warhead-based design strategies, employing different reactive groups to covalently attack the catalytic cysteine residue. Warheads utilised include Michael acceptors, aldehydes, epoxy ketones and other ketones.
 <xref rid="b0360" ref-type="bibr">
  <sup>72</sup>
 </xref>
</p>
